<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01509976</url>
  </required_header>
  <id_info>
    <org_study_id>AVOCET</org_study_id>
    <nct_id>NCT01509976</nct_id>
  </id_info>
  <brief_title>Triclosan, Triclocarban, and the Microbiota</brief_title>
  <official_title>Triclosan, Triclocarban, and the Microbiota</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Triclosan (5-chloro-2 (22,4-dichlorophenoxy)phenol) is a broad-spectrum antibacterial and&#xD;
      antifungal agent that is found in thousands of common household products, including&#xD;
      deodorants, toothpaste, &quot;antibacterial&quot; soaps, cleaning products, kitchen utensils, bedding,&#xD;
      socks, trash bags. The benefits of triclosan have not been proven except in reducing plaque&#xD;
      and gingivitis when used in toothpaste. In this study, the investigators intend to look at&#xD;
      whether exposure to triclosan changes the colonizing flora of the skin, gut and mouth as well&#xD;
      as changes in certain blood hormone levels, including adipocytokines, androgens, and&#xD;
      inflammatory markers. Changes in the gut microbiota have been associated with a variety of&#xD;
      disease states such as inflammatory bowel disease, colorectal cancer. Additionally,&#xD;
      reductions in the microbiome diversity have been associated with obesity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: Exposure to triclosan changes microbial flora and leads to changes in&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        1. Assess diversity and quantities of microbial flora in gut, skin, mouth before, during,&#xD;
           and after TC use&#xD;
&#xD;
        2. Assess whether TC use correlates with microbial resistance&#xD;
&#xD;
        3. If any, assess time to change in alterations in microbial flora&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Prospective, randomized, double-blinded, cross-over study of 20 subjects&#xD;
&#xD;
      Here, we propose a pilot study in which we will compare the microbial flora of subjects who&#xD;
      use triclosan-containing personal hygiene products and those who use triclosan-free products.&#xD;
      We will randomize half the cohort to triclosan-containing personal hygiene products including&#xD;
      toothpaste, liquid hand soap, bar soap, and dish soap for half of the cohort for a 5-month&#xD;
      period of time. The participants and investigators will be blinded as to whether they are&#xD;
      using triclosan-containing products or triclosan-free products by blinding the packaging.&#xD;
      After about 5 months, the participants will cross-over to the other arm.&#xD;
&#xD;
      During a lead-in period of about 2 weeks, we will collect urine samples for a baseline&#xD;
      triclosan level and body weight. We will also collect Leptin, Resistin, Grehlin, IL 10, IL17,&#xD;
      PAI-1 Plasminogen activator inhibitor -1, TNFa, IFN-g, Insulin, IGF, Glucagon, CRP, TSH, Free&#xD;
      T4T3, Estradiol, Testosterone free, Testosterone total, Adiponectin, IL6, Visfatin, H.&#xD;
      pylori, ESR. Blood, urine, and body weight will be collected at three points in the study:&#xD;
      prior to first phase, in between phases, and after completion of second phase.&#xD;
&#xD;
      We will collect stool, skin, tooth, and saliva samples multiple times throughout the study&#xD;
      and submit for pyrosequencing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2011</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">October 1, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in microbial flora</measure>
    <time_frame>5 months in each phase for a total of 10 month study period</time_frame>
    <description>We will assess diversity and quantities of microbial flora in gut, skin, mouth before, during, and after triclosan use.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbial resistance</measure>
    <time_frame>5 months in each phase for a total of 10 month study period</time_frame>
    <description>We will assess whether triclosan use correlates with microbial resistance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to alteration in flora.</measure>
    <time_frame>5 months in each phase for a total of 10 month study period</time_frame>
    <description>We will assess time to change in alterations in microbial flora, if any.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Triclosan Effects on Microbial Flora</condition>
  <arm_group>
    <arm_group_label>Red</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This arm will either start with personal care products that contain triclosan and then and cross over to personal care products that do not contain triclosan or vice-versa. Since the investigators are blinded, it is not clear which arm is which.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blue</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This arm will either start with personal care products that contain triclosan and then and cross over to personal care products that do not contain triclosan or vice-versa. Since the investigators are blinded, it is not clear which arm is which.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>triclosan/triclocarban-containing personal care products</intervention_name>
    <description>Subjects will be randomly assigned to one of two arms with either triclosan/triclocarban-containing personal care products or products without triclosan/triclocarban. After 5 months, each subject will cross over to the other arm.</description>
    <arm_group_label>Blue</arm_group_label>
    <arm_group_label>Red</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Health subjects&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Recent travel to the developing world (within 3 months)&#xD;
&#xD;
          -  Recent use of antibiotics (within 3 months)&#xD;
&#xD;
          -  Unwillingness to change personal care/hygiene products&#xD;
&#xD;
          -  Recent gastrointestinal illness (within 3 months)&#xD;
&#xD;
          -  Individuals who are unlikely to be available for the 10 months of the study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, Egholm M, Henrissat B, Heath AC, Knight R, Gordon JI. A core gut microbiome in obese and lean twins. Nature. 2009 Jan 22;457(7228):480-4. doi: 10.1038/nature07540. Epub 2008 Nov 30.</citation>
    <PMID>19043404</PMID>
  </reference>
  <reference>
    <citation>Russell AD. Whither triclosan? J Antimicrob Chemother. 2004 May;53(5):693-5. Epub 2004 Apr 8. Review.</citation>
    <PMID>15073159</PMID>
  </reference>
  <reference>
    <citation>Queckenberg C, Meins J, Wachall B, Doroshyenko O, Tomalik-Scharte D, Bastian B, Abdel-Tawab M, Fuhr U. Absorption, pharmacokinetics, and safety of triclosan after dermal administration. Antimicrob Agents Chemother. 2010 Jan;54(1):570-2. doi: 10.1128/AAC.00615-09. Epub 2009 Oct 12.</citation>
    <PMID>19822703</PMID>
  </reference>
  <reference>
    <citation>Guyer B, Freedman MA, Strobino DM, Sondik EJ. Annual summary of vital statistics: trends in the health of Americans during the 20th century. Pediatrics. 2000 Dec;106(6):1307-17.</citation>
    <PMID>11099582</PMID>
  </reference>
  <reference>
    <citation>Cummings DE, Schwartz MW. Genetics and pathophysiology of human obesity. Annu Rev Med. 2003;54:453-71. Epub 2001 Dec 3. Review.</citation>
    <PMID>12414915</PMID>
  </reference>
  <reference>
    <citation>Charles J, Pan Y, Britt H. Trends in childhood illness and treatment in Australian general practice, 1971-2001. Med J Aust. 2004 Mar 1;180(5):216-9.</citation>
    <PMID>14984340</PMID>
  </reference>
  <reference>
    <citation>Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989 Nov 18;299(6710):1259-60.</citation>
    <PMID>2513902</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 6, 2012</study_first_submitted>
  <study_first_submitted_qc>January 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2012</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Julie Parsonnet</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Triclosan</keyword>
  <keyword>Triclocarban</keyword>
  <keyword>Microbial flora</keyword>
  <keyword>Obesity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triclosan</mesh_term>
    <mesh_term>Triclocarban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

